Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.
- DOI
- 10.1111/ene.70628
- Published
- 2026 Jun
- Container
- European journal of neurology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/ene.70628,
title = {Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.},
author = {Vermersch P and Benedict RHB and Van Wijmeersch B and Cutter G and Kister L and Oreja-Guevara C and Siva A and Wiendl H and Wuerfel J and El Azzouzi B and Kuenzel T and Buffels R and Craveiro L and Dirks P and Comi G},
year = {2026},
journal = {European journal of neurology},
doi = {10.1111/ene.70628},
url = {https://doi.org/10.1111/ene.70628}
}RIS
TY - JOUR TI - Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial. AU - Vermersch P AU - Benedict RHB AU - Van Wijmeersch B AU - Cutter G AU - Kister L AU - Oreja-Guevara C AU - Siva A AU - Wiendl H AU - Wuerfel J AU - El Azzouzi B AU - Kuenzel T AU - Buffels R AU - Craveiro L AU - Dirks P AU - Comi G PY - 2026 JO - European journal of neurology DO - 10.1111/ene.70628 UR - https://doi.org/10.1111/ene.70628 ER -
APA
P, V., RHB, B., B, V. W., G, C., L, K., C, O., A, S., H, W., J, W., B, E. A., T, K., R, B., L, C., P, D., & G, C. (2026). Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.. European journal of neurology. https://doi.org/10.1111/ene.70628
Source records
- pubmed · retrieved 2026-09-25T10:10:06.971Z